Research on immune checkpoint blockade therapy has made great progress in cancer immunotherapy, but the number of patients who benefit from this therapy remains limited. In this study, we examined the effects of monotherapy with systemic low-dose resiquimod, a synthesized TLR7 agonist, and examined its combined effects with PD-L1 blockade in two PD-L1 blockade-resistant tumor models (SCCVII and Colon 26 
INTRODUCTION
The blockade of immune checkpoint molecules, such as CTLA-4 and PD-1, efficiently enhances antitumor immune responses by eliminating the immunoregulatory function of effector T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumorassociated macrophages (TAMs) [1] [2] [3] [4] . However, individual patients who receive the benefits of immune checkpoint blockade differ greatly by clinical grade and tumor tissue type. Head and neck cancers (HNCs) do not frequently express the tumor-specific mutated antigens (called "neoantigens") that elicit T-cell immunoreactivity and influence sensitivity to immune checkpoint blockade
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therapy [5, 6] , and their tumor microenvironment (TME) contains abundant regulatory cells, such as Tregs and MDSCs [7] [8] [9] . We recently demonstrated that blockade of either CTLA-4 or PD-1 efficiently inhibited the tumor growth of a murine squamous cell carcinoma (SCC) cell line (SCCVII) in syngeneic mice; however, we failed to eradicate the tumors [10] . The ratio of effector CD8 + T cells/Tregs (CD8/Treg) closely associated with the prognosis and outcome of immunotherapy [10, 11] .
Toll-like receptors (TLRs) recognize a wide panel of exogenous and endogenous ligands, and the binding of natural and synthetic TLR ligands to TLRs induces multiple cytokine production, resulting in enhanced innate and adaptive immunity [12] [13] [14] . Small compounds that are designed to bind TLRs are potential drugs for vaccines and adjuvants in infectious disease and cancer. TLR7 and TLR8, which are expressed on endosomes, have structural similarity and recognize microbial single-stranded RNA (ssRNA). Imiquimod (R837) and resiquimod (R848), which are imidazoquinoline compounds of synthesized ssRNAs, bind TLR7 alone and both TLR7 and TLR8, respectively [15, 16] . Resiquimod does not exert mouse TLR8-mediated activation. TLR7/8-mediated signaling induces the production of NF-kB-mediated proinflammatory cytokines and chemokines, and type I interferon (IFN) by activating antigen-presenting cells (APCs), resulting in the augmentation of effector T cells [12, 17, 18] . Nevertheless, imidazoquinolines have been applied in the clinical setting only in the form of a topical treatment or a locally administrated drug for the treatment of non-melanoma skin cancers and viral skin lesions to avoid TLR tolerance and adverse proinflammatory and proapoptotic effects [19] [20] [21] [22] .
Recently, systemic or intratumoral administration of TLR7 agonists, such as resiquimod and its related conjugate, has shown to induce efficient tumor regression by inhibiting TAM-or MDSC-mediated immune suppression in murine tumor models [23, 24] . In PD-1 blockade therapy-resistant and immunosuppressive tumors, such as HNC, combined treatment with a TLR7 agonist and PD-1 blockade might be an effective cancer immunotherapy. In this study, we examined the effects of monotherapy of systemic lowdose resiquimod and combined therapy with anti-PD-L1 treatment in two PD-L1 blockade-resistant tumor models.
RESULTS
The TME of SCCVII presents a more immunosuppressed status Colon 26 is a carcinogen-induced undifferentiated colon carcinoma cell line that originated from BALB/c mice, and SCCVII is a spontaneously arising SCC cell line derived from C3H/HeN (C3H) mice [25, 26] . PD-1:PD-L1 blockade therapy in these tumor models did not completely eradicate the tumors in syngeneic mice ( [10] and data discussed below). Although both cultured tumor cell lines showed no or marginal PD-L1 expression, IFN-γ treatment for 72 hr efficiently increased its expression ( Figure 1A) . Furthermore, immunohistochemistry showed that subcutaneously inoculated tissue tumor cells expressed PD-L1; however, its expression levels varied by lesions ( Figure 1B) . PD-L1 expression in both tumors is inducible in vitro and in vivo. To investigate the differences between the host immune responses in both tumors, we examined the phenotypes and activation status of tumor infiltrating lymphocytes (TILs). Compared with Colon 26, CD45
+ pan-leukocytes in the SCCVII-TIL fractions contained a lower percentage of CD3 + T and a greater percentage of CD11b + myeloid cells ( Figure 1C ). These CD11b + cells presented with high forward scatter, and antigenic profiles that were Gr-1-negative and F4/80-positive, indicating a phenotype consistent with TAMs (Supplementary Figure 4A) . CD3
+ T cells in SCCVIITILs had a significantly lower percentage of CD8 + T and a greater percentage of CD4
+

Foxp3
+ Tregs. Furthermore, a significantly lower proportion of CD8 + T cells expressed IFN-γ. These results show that the TME in SCCVII had impaired effector cytotoxic T lymphocytes (CTLs) and a high recruitment of immunoregulatory TAMs and Tregs.
Systemic low-dose resiquimod administration induces a transient upregulation of serum IFN-α
To avoid unwanted proinflammatory cytokine production by systemic resiquimod injection, we first used a low dose (1.7 μg/mouse) of resiquimod compared with the dose of other imidazoquinoline-like molecules injected in mice [23, 27] . Serum proinflammatory cytokines in intact and SCCVII tumor-inoculated C3H mice were measured. At 3 hr after resiquimod injection, serum IFN-α increased transiently, but it returned to an undetectable level at 12 hr (Table 1) . Similar to IFN-α, IL-6 also increased at 3 hr, albeit only slightly, and was undetectable at 12 hr. This dose of resiquimod did not increase IL-1β and TNF-α. Tumor inoculation slightly upregulated serum IFN-α and IL-6 production, but these diminished quickly. These results indicate that systemic injection of a low-dose of resiquimod did not induce the production of multiple proinflammatory cytokines, but induced temporal activation of plasmacytoid DCs (pDCs), that expressed high levels of TLR7 [28] , which may contribute to the selective and transient upregulation of IFN-α.
Systemic low-dose resiquimod administration efficiently reduces tumor growth and enhances the efficacy of PD-L1 blockade therapy
We examined the effects of monotherapy with either PD-L1 blockade or resiquimod, and of combined therapy in two tumor models (Colon 26 and SCCVII). The addition of resiquimod to each tumor cell culture did not clearly affect tumor growth, indicating that both tumor cells did not directly respond to resiquimod. In preliminary experiments, treatment started at day 0 (early treatment) and day 7 (delayed treatment). Although the delayed treatment in SCCVII tumors showed effects comparable to those of the early treatment, the delayed treatment worsened the effects in Colon 26. Thus, thereafter, we used only early treatment for Colon 26 and delayed treatment for SCCVII. Treatment with anti-PD-L1 monotherapy did not clearly affect the tumor growth of Colon 26 ( Figure 2A) . A similar treatment in SCCVII slightly decreased the tumor volume, and the growth curves of individual SCCVII tumors reflected three response groups (resistant, moderate, and sensitive) ( Figure 2B ). Resiquimod monotherapy markedly inhibited tumor growth in both tumor models, and its inhibitory effect was much more obvious in SCCVII. Regarding Colon 26 tumors, an assessment of mean tumor volume did not show combined effects, but individual growth curves showed bilateral groups of tumor size (large and small) (Figure 2A ). It should be noted that the images of the resected tumors in the combined therapy showed clear and widespread necrotic lesions with a dark red color, especially in the large tumor masses (Figure 2A ). This suggests additional antitumor effects in Colon 26 by the combined therapy. In SCCVII tumors, the combined therapy gradually decreased tumor growth from day 13 to the final observation day (day 19) , and the mean tumor volume on the final day was significantly reduced ( Figure 2B ). The tumor size in over half the mice remained unchanged in the last 4 days, and five mice showed only scar-like lesions, suggesting almost complete eradication of the tumors. Our results demonstrate that systemic low-dose resiquimod administration efficiently reduced tumor growth, and combined treatment with PD-L1 blockade exerted additional effects in two tumor models. + and CD4 + Tcon cells were determined on the final day. In Colon 26 tumors, no T-cell subset was clearly affected by either monotherapy, but the combined treatment significantly decreased the Treg proportion compared with the control and PD-L1 blockade groups ( Figure 3A) . This resulted in an increase in the CD8/Treg ratio. IFN-γ expression levels in both CD8 + T and Tcon were increased by the combined treatment, although the difference was not statistically significant. Interestingly, resiquimod monotherapy in SCCVII efficiently increased the proportion of CD8 + T cells and decreased the proportion of Tregs, resulting in a marked elevation of the CD8/Treg ratio in some mice ( Figure 3B ). PD-L1 blockade alone also significantly increased the percentage of CD8 + T cells and the CD8/Treg ratio. An additional resiquimod treatment combined with PD-L1 blockade further decreased the proportion of Tregs and resulted in an improved CD8/Treg ratio in most mice. Consistent with the findings in Colon 26 tumors, the expression levels of IFN-γ in both CD8 + T and Tcon were not clearly affected. These results indicate that systemic administration of low-dose resiquimod in the Treg-dominant SCCVII markedly decreased the proportion of Tregs and reciprocally promoted CTL recruitment in the TME. Unlike the findings for SCCVII, similar treatment in a relatively CTL-rich Colon 26 tumor model reduced Treg recruitment without affecting CTLs. Taken together, our results indicate that systemic low-dose resiquimod administration in addition to PD-L1 blockade is especially effective for elevating the CD8/Treg ratio in the TME.
Resiquimod combined with PD-L1 blockade modulates recruitment of CD8 + T cells and Tregs in the TME
Resiquimod quickly enhances activation of two types of DCs
To understand the mechanisms by which systemic low-dose resiquimod administration enhanced antitumor responses by modulating Tregs and CD8 + T cells, we examined much earlier time points after resiquimod injection, focusing on DC function. We showed that serum IFN-α was transiently upregulated at 3 hr after resiquimod injection (Table 1) ; thus, DCs, especially pDCs, might have been targeted by resiquimod, as pDCs express high levels of TLR7 [28] . We examined the expression of IL-12, MHC class II, and CD86 in PDCA-1 + pDCs and PDCA-1 -conventional DCs (cDCs) in regional lymph nodes (RLNs). As expected, resiquimod application induced IL-12 expression by pDCs at 3 hr. IL-12 expression then declined at 12 hr ( Figure 4A and 4C) , with kinetical change similar to that of IFN-α as shown in Table 1 . Cell surface MHC class II and CD86 expression, which are critical for antigenpresenting capacity, were also increased on pDCs, with peak expression at 12 hr ( Figure 4B and 4C ). In the case of cDCs, transient upregulation of IL-12 was a little delayed (at 12 hr), and there was a simultaneous upregulation in MHC class II and CD86 expression. In particular, MHC class II high CD86
high fraction in cDCs was dramatically increased after 12 hr ( Figure 4B , right panels). The upregulated expression of MHC class II and CD86 were maintained until 24 hr. To examine whether cDC activation by resiquimod is dependent on pDC, we compared IL-12 expression by cDCs in vitro using whole and pDC-depleted splenocytes. Even after depletion of pDCs, resiquimod stimulation induced a comparable level of IL-12 expression (Supplementary Figure 1) , suggesting that resiquimod can directly activate cDCs without pDC-mediated help. These results indicate that systemic resiquimod administration augmented the activation of both pDCs and cDCs in the circulation and RLNs.
Resiquimod enhances activation of CD8
+ T cells in RLNs and the TME 
A limited dose of resiquimod exerts combinational effects with PD-L1 blockade therapy
Our results suggest that resiquimod may be used as a companion drug for PD-1/PD-L1 blockade therapy. We titrated the concentration of resiquimod (0.4, 0.8, and 1.7 μg/mouse) and examined the tumor volume of SCCVII. The inhibitory effects of resiquimod monotherapy were dose-dependent, and doses of 0.8 and 0.4 μg showed marginal effects ( Figure 6A ). Additionally, we examined the effects of limited doses (1.0 and 0.5 μg/mouse) of resiquimod in addition to the PD-L1 blockade. Although these doses were not effective in monotherapy, additional resiquimod treatment along with the PD-L1 blockade further decreased the tumor volume ( Figure 6B ). We next examined whether the decreased frequency of anti-PD-L1 therapy was still effective when it was combined with resiquimod. We decreased the frequency of anti-PD-L1 treatment to the half (from twice per week to once per week). The decreased frequency of anti-PD-L1 therapy under the resiquimod treatment consistently showed comparable effects ( Figure 6C ). These results suggest that limited doses of systemic resiquimod administration enable to overcome resistance to PD-L1 blockade, and allow for the decreased usage of the anti-PD-L1 antibody.
DISCUSSION
We demonstrated the differential effects of systemic low-dose resiquimod administration in monotherapy and in combined treatment with PD-L1 blockade in two PD-L1 blockade-resistant tumor models that exhibit different profiles of TILs. Resiquimod monotherapy resulted in some tumor reduction in Colon 26, and showed a relatively higher recruitment and activation of CD8 + T cells in the TME. Combined treatment did not clearly affect outside tumor size, but it did augment the necrotic lesions of inside tumors that were correlated with a marked reduction of Tregs in the TME. Unlike Colon 26 tumors, resiquimod monotherapy in SCCVII tumors with impaired CD8 + T cell activation and accelerated Treg recruitment in the TME markedly decreased tumor size along with CD8 + T cell accumulation and a reduction of Tregs. Combined resiquimod treatment with PD-L1 blockade exerted additional effects on tumor size and Treg and CD8 + T cell recruitment. Our results indicate that the efficacy of systemic resiquimod administration is highly superior in Tregdominant tumors, such as SCCVII. This suggests that low-dose resiquimod administration converts resistance to PD-L1 blockade therapy that is caused by Treg accumulation. We previously reported that Treg depletion in a SCCVII model resulted in almost complete eradication of tumors [29] ; thus, Tregs are critical immune regulators that accelerate SCCVII tumor growth. Even in Colon 26, combined treatment decreased Treg accumulation, resulting in expansion of the necrotic area. In both tumor models, resiquimod treatment was efficacious because it resulted in Treg attenuation in the TME. Previous reports using a relatively high dose of TLR7/8 agonists (resiquimod and loxoribin) also demonstrated de novo inhibition of Tregs via modulation of DCs and involvement of IL-6 [30, 31] . Resiquimod-treated DCs have been shown to downregulate Foxp3 expression and suppress the function of Tregs [30] . We also observed that generation of induced Tregs was 
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+ T cells and OVA-pulsed DCs (Supplementary Figure 2) . IL-6 production in the pre-DC culture in the presence of OVA and a maturation-cytokine, TNF-α increased almost tenfold by resiquimod stimulation (the mean ± SD; without resiquimod, 74.7 ± 42.3 pg/ml and with resiquimod, 650.6 ± 44.5 pg/ml). This suggests that resiquimod-treated DCs inhibit Treg generation and IL-6 secreted from resiquimodactivated DCs might be a candidate cytokine involved in Treg inhibition.
In this study, we observed that systemic administration of low-dose resiquimod induced a transient (3 hr) upregulation of IFN-α in sera and IL-12, MHC class II, and CD86 expression by pDCs in the RLNs. Thus, pDCs in the circulation, including tumor sites and secondary lymphoid organs, are the initial responsive target cells for resiquimod. We also observed that resiquimod stimulation in vitro efficiently increased CD8 + PDCA-1 + DCs and pre-depletion of pDC failed to increase CD8 + DCs (Supplementary Figure 3) . It has been shown that unlike regular splenic pDCs, TLR ligand-activated pDCs play a critical role in the cross-priming of tumoral-antigens to generate effector CTLs in RLNs [32] . Although we have not directly examined function of resiquimod-treated pDCs, it is possible that resiquimod-stimulated CD8 + pDCs may contribute to cross-priming. However, pDCs licensed by TLR ligands alone fail to induce efficient CTLs and cooperate with other RLN cDCs or a subset of XCR1 + DCs to promote T-cell recruitment and activation [33] [34] [35] . Thus, it is likely that activation of pDCs and cDCs by systemic resiquimod injection and cooperation by both types of licensed DCs amplify T-cell priming against tumor antigens, resulting in efficient induction of CTLs and attenuation of Treg generation. This may explain why lowdose resiquimod efficiently affects the numbers of CD8 + T, Tregs, and the CD8/Treg ratio.
We cannot presently rule out the involvement of TAMs or MDSCs in resiquimod action. TILs from SCCVII tumor-bearing mice contained a greater proportion of CD11b + TAMs, which was decreased by resiquimod monotherapy (Supplementary Figure 4B) . Recent reports demonstrated that intratumoral injection of a phospholipidconjugated TLR7 agonist increased the ratio of M1/M2 TAMs in several tumor models [24] , and subcutaneous injection of resiquimod in CT26 tumors converted monocytic MDSCs into non-suppressive state [23] . Further studies are required to clarify their involvement.
Nevertheless, our results indicate that systemic administration of low-dose resiquimod as a companion drug with PD-1/PD-L1 blockade therapy offers considerable benefits. Although the effects of intratumoral injection of a TLR7/8 agonist (3M-052/ MEDI9197) alone and in combination with anti-PD-L1 antibody (durvalumab) against solid tumors are being studied in a clinical trial (ClinicalTrials.gov #NCT02556463), intratumoral injection requires the selection of eligible cases and the use of special techniques by medical professionals. Systemic administration is much more convenient and broadly applicable. Once a suitable dose that does not cause adverse effects, as represented by acute proinflammatory cytokine secretion, is determined for clinical use, systemic administration of low-dose resiquimod combined with PD-1/PD-L1 blockade therapy, especially in immunosuppressive tumors, such as HNC, may have a great potential to eradicate tumors. Our results suggest that systemic administration of low-dose resiquimod is useful as a companion drug with PD-1/PD-L1 blockade therapy.
MATERIALS AND METHODS
Mice
Female 6-7-week-old BALB/c and C3H mice were purchased from Japan SLC (Hamamatsu, Japan). All mice were maintained under specific pathogen-free conditions at Tokyo Medical and Dental University. All experimental procedures were reviewed and approved by the Animal Care and Use Committee of Tokyo Medical and Dental University (0170344A).
Tumor cell lines and treatment
Two tumor cell lines, SCCVII (a spontaneously arising squamous cell carcinoma cell line derived from C3H mice, 2 × 10 5 cells) [10, 25, 26, 29] and Colon 26 (a carcinogen-induced undifferentiated colon carcinoma cell line originated from BALB/c mice, 5 × 10 5 cells) [29, 36, 37] were used. For induction of PD-L1 in vitro, cells were cultured in the presence or absence of IFN-γ (10 ng/ml, BD Biosciences, San Diego, CA) for 72 hr. Cultured tumor cells were freeze-stocked at the same time, and cells that had been cultured for 5-7 days were used for tumor inoculation. Tumor cells were injected subcutaneously (s.c.) into the shaved right flank of syngeneic mice, and tumor size was measured as described previously [10, 29] . Resiquimod was synthesized with ≥98% purity by a contract research organization and provided in lyophilized form. Comparable activity with R848 purchased from InvivoGen (San Diego, CA) was validated by IFN-α, IL-12 and TNF-α secretion using mouse and human pan-DC fractions by ELISA. In most experiments, unless otherwise noted, treatment with either resiquimod (1.7 μg/mouse) or anti-PD-L1 mAb (MIH5, rat IgG2a, 200 μg/mouse) [38] , or with both was started at day 0 for Colon 26 and day 7 for SCCVII by intraperitoneal (i.p.) injection twice per week until day 17.
Isolation of TILs and LN cells
To isolate TILs, resected tumor masses were minced and digested with collagenase I, hyaluronidase, and DNase as described previously [39] . Then alive cells were separated using a lymphocyte separation medium. RLNs were collected from the tumor-inoculated side of inguinal and axillary LNs. For analysis of DCs, RLN cells were isolated using type I collagenase as described previously [40] .
Monoclonal antibodies and flow cytometry
Monoclonal antibodies (mAbs) against CD3 (17A2, rat IgG2b), CD4 (GK1.5, rat IgG2b), CD8 (53-6.72, rat IgG1), CD45 (30-F11, rat IgG2b), IFN-γ (XMG1.2, rat IgG1), Foxp3 (FJK-165, rat IgG2a), CD11b (M1/70, rat IgG2b), CD11c (N418, Armenian hamster IgG), PDCA-1 (eBio927, rat IgG2b), CD86 (PO3.1, rat IgG2b), MHC class II (M5/114, rat IgG2b), PD-L1 (MIH5, rat IgG2a), IL-12/IL-23 p40 (C17.8, rat IgG2a), and Ki-67 (Sola15, rat IgG2a) were used. All FITC-, PE-, APC-, PerCP-Cy5.5-, PE-Cy7-, APC-eFluor780-, V450-, and Brilliant Violet 510-conjugated mAbs were obtained from eBioscience (San Diego, CA), BD-Biosciences or Biolegend (San Diego, CA). Non-specific binding via FcγR and multicolor cell staining for cell surface and intracellular molecules was performed as described previously [10] . Stained cells were analyzed using FACSCalibur or FACSVerse (BD Biosciences) with Cell Quest Pro or FACSuite software. All data were analyzed using FlowJo software (Tree Star, Ashland, OR).
Assessment of serum proinflammatory cytokines and activation status of DCs after resiquimod injection
Cultured SCCVII cells were 40-Gy irradiated to stop cell growth. Intact or irradiated-SCCVII tumor-(1 × 10 6 cells/site) inoculated mice received i.p. administration of resiquimod (1.7 μg/mouse); then, blood and RLNs (inguinal and axillary LNs) were collected at the indicated time points. Serum cytokines (IFN-α, IL-1β, IL-6, and TNF-α) were measured using ELISA kits according to the manufacture's protocol (eBioscience). For measurement of intracellular IL-12, cells were cultured in the presence of brefeldin A for 3 hr.
Immunohistochemistry
Cryostat sections (6 μm) of tumor tissue were stained with anti-PD-L1 (MIH6, rat IgG2a), and enzymatic immunohistochemistry was performed as described previously [38] .
Statistical analysis
Statistical analyses were performed using the MannWhitney U-test or the Mann-Whitney U-test with Bonferroni correction. Statistical significance was set at p < 0.05.
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